Table 2 Dose levels, schedule, and dose-limiting toxicity.

From: Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Dose level

CX-5461 dose (mg/m2/dose)

Schedule (Q4 weeks)

Planned dose/week (mg/m2)

Number enrolled

Dose-limiting toxicities

0

50

Day 1 & 8

25

4

 

1

100

50

4

 

2

150

75

4

 

3

200

100

4

 

4

250

125

3

 

5

325

163

3

 

6

475

238

3

 

7

325

Day 1, 8 & 15

244

4

 

8

475*

356

6

 

9

650

488

5

2 **

  1. *Includes 1 patient treated in the expansion phase.
  2. **One occurred after cycle 1 (phototoxicity (skin and eye)).
Back to article page